|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ASCO officially starts next week, but inside today's newsletter, we've got a look at the abstracts released this afternoon. This year is shaping up to be the busiest in recent memory, with important findings coming in VEGF/PD-1 trials, ADCs and pancreatic cancer. There's more to come — and be sure to join us at Endpoints at ASCO '26 on June 3 as we break it all down. Register here. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Max Gelman
|
Much of the attention heading into the annual ASCO meeting next week has focused on Summit Therapeutics and Akeso’s plenary presentation for their bispecific drug... | |
|
|
|
|
|
|
|
|
by Max Gelman
|
Merck partner Kelun-Biotech fleshed out a Phase 3 win in lung cancer from a study in China for the experimental antibody-drug conjugate sac-TMT, raising hopes... | |
|
|
|
|
|
|
by Ayisha Sharma
|
Head and neck cancer has always been a tough nut to crack. These tumors can suppress immune responses through multiple pathways, meaning blocking one of... | |
|
|
|
|
|
|
by Lei Lei Wu
|
It’s no secret that Akeso’s presentation will be one of the most closely watched readouts from the American Society of Clinical Oncology annual meeting this... | |
|
|
|
 |
|
Marty Makary (Aaron Schwartz/Sipa USA/Sipa via AP Images) |
|
|
|
by Max Bayer
|
Biohaven CEO Vlad Coric finally had the attention of the FDA, and most importantly, Commissioner Marty Makary. In late April, after the company’s spinocerebellar ataxia... | |
|
|
|
|
|
|
by Andrew Dunn
|
Over a 35-year history, Incyte has grown into a $19 billion biopharma company. The Delaware-based drugmaker is now turning to AI to power through the... | |
|
|
|
|
|
